Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cygnus/Yamanouchi

This article was originally published in The Gray Sheet

Executive Summary

Cygnus/Yamanouchi: Sign marketing and distribution agreement under which Tokyo-based Yamanouchi Pharmaceutical gains exclusive rights to sell the GlucoWatch continuous glucose monitoring device in Japan and Korea. According to terms of the deal, Redwood City, California-based Cygnus will have "primary responsibility" for completing product development and for manufacturing. Cygnus could receive up to $10 mil. in up-front and milestone payments under the deal; the agreement also includes royalties. In a pact announced in February, Cygnus licensed GlucoWatch to Becton Dickinson for all markets except Japan and Korea ("The Gray Sheet" Feb. 19, I&W-9)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel